Groover Jr., M. E.; Stout, Clarke
February 1966
Angiology;Feb1966, Vol. 17 Issue 2, p85
Academic Journal
Serial observations of the physiochemical properties of human blood measured by electrophoresis and fractional centrifugation of red cells show a marked variation from time to time, similar to that experimentally produced in animals, and associated with alterations in the size and composition of experimental thrombi. The degree of variation is greater in postmyocardial infarction patients than in healthy controls. Shortening of β-lipoprotein mobility and increased red cell compressibility are associated with emotional tension and allergic manifestations. The reverse is produced by heparin administration.


Related Articles

  • mural thrombus. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p521 

    An encyclopedia entry for the term "mural thrombus" is presented. It refers to a thombus or blood clot on the inner wall of a heart chamber. The clot, which usually occurs in the lower chamber, develops on a tissue portion that has been damaged by a myocardial infarction.

  • Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis. Morel, O.; Jesel, L.; Freyssinet, J. M.; Toti, F. // Thrombosis Journal;2005, Vol. 3, p15 

    Circulating procoagulant microparticles (MP) are pathogenic markers of enhanced coagulability associated to a variety of disorders and released from stimulated vascular cells. When derived from endothelial cells, MP were found characteristic of thrombotic propensity in primary antiphospholipid...

  • False Positive Cardiac Troponin Results in Patients Without Acute Myocardial Infarction. Gifford Lum; David E. Solarz; Linda Farney // Laboratory Medicine;Sep2006, Vol. 37 Issue 9, p546 

    Cardiac troponin I (cTnI) and T (cTnT) are highly sensitive and specific biochemical markers for myocardial necrosis and are generally not elevated in cases other than acute myocardial infarction (AMI) and acute coronary syndrome (ACS). However, if the patient's clinical picture for AMI or ACS...

  • A Rare Presentation of Primary Antiphospholipid Syndrome. Prashanth, Panduranga; Mukhaini, Mohammed; Riyami, Abdulla // Oman Medical Journal;Oct2009, Vol. 24 Issue 4, p300 

    This case presents a young patient with myocardial infarction, in-situ thrombosis of left anterior descending coronary artery and right common-iliac artery due to primary antiphospholipid syndrome. This report discusses the relationship between antiphospholipid antibodies and coronary artery...

  • Anticoagulation therapy. Kakar, Puneet; Lip, Gregory Y. H. // GP: General Practitioner;12/8/2006, p22 

    The article presents information on the use of anticoagulation therapy in the treatment of acute coronary syndromes and acute cerebral ischaemic syndromes. Anticoagulants like warfarin and heparin are used in the therapy to prevent blood coagulation. Therapeutic anticoagulation avoids...

  • Coronary artery ectasia as a culprit for acute myocardial infarction: review of pathophysiology and management. Boles, Usama; Rakhit, Roby; Man Fi Shiu; Patel, Ketna; Henein, Michael // Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi;Nov2013, Vol. 13 Issue 7, p695 

    Coronary artery ectasia (CAE) is defined as localized coronary dilatation, which exceeds the diameter of normal adjacent segments or the diameter of the patient's largest coronary vessel by 1.5 times. The pathophysiology of CAE remains unclear as its relationship with atheroscle-rosis remains...

  • Long-Term, Low-Dose Aspirin Therapy.  // HealthFacts;Nov2006, Vol. 31 Issue 11, p3 

    The article discusses research on the bleeding risk of lifelong regimen of Plavix to prevent a heart attack or stroke. According to researchers at the Veterans Affairs Medical Center in San Francisco, California, the odds of harm of anti-clotting drug Plavix were low. A trial involving a...

  • Fatal Blood Clot Genetic Risk Identified.  // Trends in Medical Research;2011, Vol. 6 Issue 1, p46 

    No abstract available.

  • Life-threatening cardiac manifestations of primary antiphospholipid syndrome. Grzybczak, Rafal; Undas, Anetta; Rostoff, Pawel; Gackowski, Andrzej; Czubek, Urszula; Stopyra, Katarzyna; Piwowarska, Wieslawa // Heart & Vessels;May2010, Vol. 25 Issue 3, p267 

    We report a rare case of primary antiphospholipid syndrome (APS) in a 43-year-old man presenting as recurrent acute coronary stent thrombosis and complicated by three myocardial infarctions. As illustrated in this report, in APS patients recurrent life-threatening arterial thrombotic events may...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics